Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.
Reads0
Chats0
TLDR
In this article, the authors reviewed patterns of resistance to HCV DAA drugs in development, the mechanisms underlying treatment failure when these drugs are combined with pegylated interferon-α and ribavirin, and possible means of optimizing future therapies that use DAAs.About:
This article is published in Hepatology.The article was published on 2011-05-01 and is currently open access. It has received 324 citations till now. The article focuses on the topics: Telaprevir & Boceprevir.read more
Citations
More filters
Journal ArticleDOI
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
TL;DR: This review describes the different classes of drugs and their mechanisms and properties, as well as treatment strategies in development, including those that are interferon-based and interferons-free.
Journal ArticleDOI
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
TL;DR: First-line treatment strategies should be optimized to efficiently prevent treatment failure due to HCV resistance, as viral variants resistant to NS5A inhibitors at baseline is associated with lower rates of virological cure in certain groups of patients.
Journal ArticleDOI
Lancet Seminar – Hepatitis C
TL;DR: Advances in HCV cell culture have enabled improved understanding of HCV virology, which has led to development of many new direct-acting antiviral drugs that target key components of virus replication, allowing for simplified and shortened treatments for HCV that can be given as oral regimens with increased tolerability and efficacy.
Journal ArticleDOI
Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
TL;DR: To optimally manage hepatitis C and associated comorbidities, patients benefit from multidisciplinary teams that can provide HCV-specific care and treatment.
Book ChapterDOI
Hepatitis C Virus Entry
TL;DR: This review summarizes the current knowledge of the host factors required for the HCV-host interactions during HCV binding and entry, the understanding of the molecular mechanisms underlying HCV entry into target cells, and the relevance ofHCV entry for the pathogenesis of liver disease, antiviral therapy, and vaccine development.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
Telaprevir for retreatment of HCV infection.
Stefan Zeuzem,Pietro Andreone,Stanislas Pol,Eric Lawitz,Moisés Diago,Stuart K. Roberts,R. Focaccia,Zobair M. Younossi,Graham R. Foster,Andrzej Horban,Peter Ferenci,Frederik Nevens,Beat Müllhaupt,Paul J. Pockros,R. Terg,Daniel Shouval,Bart van Hoek,Ola Weiland,Rolf van Heeswijk,Sandra De Meyer,Don Luo,G. Boogaerts,Ramon Polo,Gaston Picchio,Maria Beumont +24 more